Recent studies proved that HMGB1 could act as an adjuvant for tuberculosis subunit vaccines to enhance the protective efficacy and cellular immune response, and these effects are not dependent on the interaction between HMGB1 and receptor 92. The gene discussed is HMGB1; the disease is tuberculosis.